impact of gambling in society
Business Editors/Health & Medical Writers JERUSALEM--(BW HealthWire)--April 26, 2000 Teva Pharmaceutical Industries Ltd.(NASDAQ:TEVA) today announced that it had received from the US Food and Drug Administration an approval to manufacture and market Ketoconazole 2% Cream. Teva USA will launch the product immediately. Ketoconazole 2% Cream is Teva's generic version of Janssen's anti-fungal drug Nizoral(R) 2% Cream, of which annual US sales are approximately $65 million. Teva views this approval as significant as it is the first approval for a generic version of this drug. Unlike most oral dosage forms, this product required a 325 patient, 18 center, double-blinded, three-way, placebo controlled clinical study to demonstrate bio-equivalence. casino poker blacjack online free online slot tournament schedules bonus casino deposit download no no casino game internet
